Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
13.91 (1y: +55%)
Market Cap 235.3 M P/E(ttm)
Enterprise Value 191.43 M P/B 2.40
DSCI- NAS (USA)
Derma Sciences, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$13.91
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry		 vs
history
Cash to Debt 168.576
DSCI's Cash to Debt is ranked higher than
70% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.63 vs. DSCI: 168.576 )
DSCI' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 168.58
Equity to Asset 0.608
DSCI's Equity to Asset is ranked higher than
58% of the 143 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.56 vs. DSCI: 0.608 )
DSCI' s 10-Year Equity to Asset Range
Min: 0.14   Max: 0.64
Current: 0.61
0.14
0.64
F-Score: 3
Z-Score: 14.62
M-Score: -2.26
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry		 vs
history
Operating margin (%) -19.90
DSCI's Operating margin (%) is ranked lower than
892856% of the 112 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 13.00 vs. DSCI: -19.90 )
DSCI' s 10-Year Operating margin (%) Range
Min: -23.8   Max: 4.7
Current: -19.9
-23.8
4.7
Net-margin (%) -16.6
DSCI's Net-margin (%) is ranked lower than
980391% of the 102 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.20 vs. DSCI: -16.6 )
DSCI' s 10-Year Net-margin (%) Range
Min: -23.8   Max: 2.4
Current: -16.6
-23.8
2.4
ROE (%) -12.9
DSCI's ROE (%) is ranked lower than
990098% of the 101 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.30 vs. DSCI: -12.9 )
DSCI' s 10-Year ROE (%) Range
Min: -77.4   Max: 5.8
Current: -12.9
-77.4
5.8
ROA (%) -11.6
DSCI's ROA (%) is ranked lower than
980391% of the 102 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.30 vs. DSCI: -11.6 )
DSCI' s 10-Year ROA (%) Range
Min: -35.3   Max: 4.1
Current: -11.6
-35.3
4.1
ROC (Joel Greenblatt) (%) -75.60
DSCI's ROC (Joel Greenblatt) (%) is ranked lower than
900900% of the 111 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.40 vs. DSCI: -75.60 )
DSCI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -104.3   Max: 15.8
Current: -75.6
-104.3
15.8
Revenue Growth (%) -11.9
DSCI's Revenue Growth (%) is ranked lower than
1176469% of the 85 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.60 vs. DSCI: -11.9 )
DSCI' s 10-Year Revenue Growth (%) Range
Min: -31.5   Max: 3.1
Current: -11.9
-31.5
3.1
EPS Growth (%) 43.3
DSCI's EPS Growth (%) is ranked higher than
88% of the 52 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 14.30 vs. DSCI: 43.3 )
DSCI' s 10-Year EPS Growth (%) Range
Min: 0   Max: 43.3
Current: 43.3
0
43.3
ยป DSCI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with DSCI



No Insider Trades Found!

Ratios

vs
industry		 vs
history
P/B 2.40
DSCI's P/B is ranked higher than
52% of the 152 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.50 vs. DSCI: 2.40 )
DSCI' s 10-Year P/B Range
Min: 0.25   Max: 7.68
Current: 2.4
0.25
7.68
P/S 2.50
DSCI's P/S is ranked lower than
55% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.30 vs. DSCI: 2.50 )
DSCI' s 10-Year P/S Range
Min: 0.05   Max: 2.46
Current: 2.5
0.05
2.46
EV-to-EBIT 55.6
DSCI's EV-to-EBIT is ranked lower than
89% of the 142 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.73 vs. DSCI: 55.6 )
DSCI' s 10-Year EV-to-EBIT Range
Min: 2.8   Max: 663.7
Current: 55.6
2.8
663.7

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 6.5
DSCI's Price/Net Cash is ranked higher than
62% of the 50 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.90 vs. DSCI: 6.5 )
DSCI' s 10-Year Price/Net Cash Range
Min: 3.9   Max: 4.6
Current: 6.5
3.9
4.6
Price/Net Current Asset Value 15.3
DSCI's Price/Net Current Asset Value is ranked lower than
51% of the 146 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 15.00 vs. DSCI: 15.3 )
DSCI' s 10-Year Price/Net Current Asset Value Range
Min: 3.4   Max: 11.1
Current: 15.3
3.4
11.1
Price/Tangible Book 3.6
DSCI's Price/Tangible Book is ranked lower than
52% of the 142 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.60 vs. DSCI: 3.6 )
DSCI' s 10-Year Price/Tangible Book Range
Min: 0.5   Max: 6.9
Current: 3.6
0.5
6.9
Price/DCF (Projected) 6.1
DSCI's Price/DCF (Projected) is ranked lower than
94% of the 65 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.50 vs. DSCI: 6.1 )
DSCI' s 10-Year Price/DCF (Projected) Range
Min: 1.1   Max: 3.8
Current: 6.1
1.1
3.8
Price/Median PS Value 4.6
DSCI's Price/Median PS Value is ranked lower than
97% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. DSCI: 4.6 )
DSCI' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 3.6
Current: 4.6
0.2
3.6
Earnings Yield (Greenblatt) 1.80
DSCI's Earnings Yield (Greenblatt) is ranked lower than
90% of the 125 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.90 vs. DSCI: 1.80 )
DSCI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 35.6
Current: 1.8
0.2
35.6
Forward Rate of Return (Yacktman) -2.03
DSCI's Forward Rate of Return (Yacktman) is ranked lower than
1960782% of the 51 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 13.37 vs. DSCI: -2.03 )
DSCI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -283.8   Max: 6.4
Current: -2.03
-283.8
6.4

Business Description

Derma Sciences, Inc. was incorporated under the laws of Colorado on September 10, 1984. On June 3, 1996, Derma Sciences changed its state of domicile to Pennsylvania. Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care, advanced wound care and traditional wound care products. The Company has one pharmaceutical wound care product candidate that has completed a Phase 2 study and is working towards initiation of a Phase 3 study in 2012. Its traditional wound care line consists of gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices; and its Pharmaceutical Wound Care include DSC127 which is patented; and its advanced wound care products include MEDIHONEY, BIOGUARD, ALGICELL AG, XTRASORB, and TCC-EZ. The Company maintains manufacturing facilities in Toronto, Canada and Nantong, China and a well-established network of third party suppliers for its products. The majority of its products are sold through distributors to various health care providers such as wound care centers, extended care facilities, acute care facilities, home health care agencies and physicians' offices. Some of its products are sold through retail channels. The Company markets its products principally through direct sales representatives in the United States, Canada and the United Kingdom, and through independent distributors within other select international markets. In the United States, its traditional wound care products compete in a commodity oriented marketplace with Covidien, Medline, Medical Action and a number of others. In the advanced wound care products marketplace, it competes with Convatec, Smith & Nephew, Molnlycke and Systagenix. Its adhesive bandage and related first aid products compete with Medline, ASO and Dynerex in the medical market, Medline and ASO in the industrial market, ASO, Medline and Liberty in the private label market and Johnson & Johnson, 3M and Medline in the retail market.
Company Website
SEC Reports
Industry: Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO
ยป More Articles for DSCI

Headlines

Articles On GuruFocus.com
Derma Sciences Inc. Reports Operating Results (10-Q) Nov 12 2010 
Derma Sciences Inc. Reports Operating Results (10-Q) May 12 2010 

More From Our Partners
Company News for May 17, 2013 - Corporate Summary May 17 2013 - ZACKS

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial